Langasog, Rudy S.
HRN: 23-51-55 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/09/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/09/2023
08/15/2023
IV
2.25gm
Q8
Acute Pyelonephritis
Waiting Final Action
Indication: EmpiricEmpirical Escalation Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes